Stock Events

Stock Events

Palvella Therapeutics 

€107
20
+€11.5+12.04% Today

Statistics

Day High
120
Day Low
120
52W High
121
52W Low
17.1
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2023
Q1 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-3.79
-2.74
-1.69
-0.64
Expected EPS
-0.766530384
Actual EPS
N/A

Financials

-944.28%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
14.76MRevenue
-139.37MNet Income

Analyst Ratings

$149.55Average Price Target
The highest estimate is 204.88.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PI6.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and inflammation, areas where Pieris also operates.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm with a broad portfolio that includes treatments in areas overlapping with Pieris' interests, such as respiratory diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in the development of therapies for serious diseases, including cystic fibrosis, a target area for Pieris' respiratory focus.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics, in areas that can compete with Pieris' pipeline.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology, autoimmune and rare diseases, but its expansion into new therapeutic areas can position it as a competitor to Pieris.
Moderna
MRNA
Mkt Cap10.61B
Moderna, known for its mRNA technology, is expanding its pipeline into diverse therapeutic areas, potentially competing with Pieris' protein engineering approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics, offering a different but competing approach to treating diseases targeted by Pieris.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a global healthcare company with a strong focus on protein-based therapies for diabetes and other serious chronic conditions, overlapping with Pieris' technology.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global biopharmaceutical company working in various therapeutic areas, including respiratory diseases, where it competes with Pieris.

About

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Stephen S. Yoder J.D.
Employees
46
Country
US
ISIN
US6979471090
WKN
000A40RA6

Listings

XNAS
US
PVLA
F
DE
PI6.F
BOATS
BOATS
PVLA.BOATS

0 Comments

Share your thoughts

FAQ

What is Palvella Therapeutics stock price today?▼
The current price of PI6.F is €107 EUR — it has increased by +12.04% in the past 24 hours. Watch Palvella Therapeutics stock price performance more closely on the chart.
What is Palvella Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Palvella Therapeutics stocks are traded under the ticker PI6.F.
Is Palvella Therapeutics stock price growing?▼
PI6.F stock has risen by +7% compared to the previous week, the month change is a -6.96% fall, over the last year Palvella Therapeutics has showed a +314.73% increase.
When is the next Palvella Therapeutics earnings date?▼
Palvella Therapeutics is going to release the next earnings report on May 14, 2026.
What were Palvella Therapeutics earnings last quarter?▼
PI6.F earnings for the last quarter are -0.89 EUR per share, whereas the estimation was -0.72 EUR resulting in a -22.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Palvella Therapeutics revenue for the last year?▼
Palvella Therapeutics revenue for the last year amounts to 14.76M EUR.
What is Palvella Therapeutics net income for the last year?▼
PI6.F net income for the last year is -139.37M EUR.
How many employees does Palvella Therapeutics have?▼
As of April 01, 2026, the company has 46 employees.
In which sector is Palvella Therapeutics located?▼
Palvella Therapeutics operates in the Health Care sector.
When did Palvella Therapeutics complete a stock split?▼
The last stock split for Palvella Therapeutics was on April 23, 2024 with a ratio of 1:80.
Where is Palvella Therapeutics headquartered?▼
Palvella Therapeutics is headquartered in Boston, US.